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A clinical practice guideline for patients in the dying process in general wards and their 
families, developed through an evidence-based process, is presented herein. The purpose of 
this guideline is to enable a peaceful death based on an understanding of suitable manage-
ment of patients’ physical and mental symptoms, psychological support, appropriate deci-
sion-making, family care, and clearly-defined team roles. Although there are limits to the 
available evidence regarding medical issues in patients facing death, the final recommenda-
tions were determined from expert advice and feedback, considering values and preferences 
related to medical treatment, benefits and harms, and applicability in the real world. This 
guideline should be applied in a way that takes into account specific health care environ-
ments, including the resources of medical staff and differences in the available resources of 
each institution. This guideline can be used by all medical institutions in South Korea.
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INTRODUCTION
With the implementation of the Act on Hospice and Pal-
liative Care and Decisions on Life-Sustaining Treatment for 
Patients at the End of Life (law 15542; hereinafter referred to 
as the Act on Decisions on Life-Sustaining Treatment), general 
end-of-life care for patients in the dying process is required 
at every medical institution. Therefore, the Korean Society 
for Hospice and Palliative Care developed an evidence-based 
clinical practice guideline for patients in the dying process in 
general wards and their family members for the first time in 
South Korea.
In this guideline, patients in the dying process are defined as 
adult patients whose death is anticipated in a few days or dur-
ing hospitalization due to cancer, chronic diseases, or acute 
deterioration of chronic organ failure after an accident, who 
do not recover despite treatment and do not have a possibility 
of recovery, who experience rapid deterioration of symptoms, 
and whose death occurs over a prolonged period due to ag-
ing or dementia. The definition is not limited to the definition 
used in the Act on Decisions on Life-Sustaining Treatment 
and reflects medical professionals’ clinical judgement. The 
aim of this guideline is to help patients in the dying process 
and their family members to prepare for death, to manage 
physical and psychological symptoms in the dying process, 
and to increase quality of life and improve satisfaction among 
patients and family members by providing psychological sup-
port and adequate decision-making so they can prepare for 
a peaceful death. A limitation is that research on patients in 
the dying process is lacking, especially large-scale studies 
that are well-designed, but this guideline was developed by 
adapting 14 existing clinical practice guidelines both locally 
and globally [1-14]. Recommendation levels were determined 
after balancing values and preferences, the benefits and risks 
of treatments, and circumstances in South Korea by agree-
ment of a multidisciplinary committee (Supplementary Table 
1). This review introduces 28 recommendations, and the full 
document can be viewed at the clinical practice guideline in-
formation center (https://www.guideline.or.kr/guide/view.
php?number=1108&cate=A).
After explaining to the patient and his or her family members 
the advantages and disadvantages of providing IV fluids and 
nutrition and the fact that there are no conclusive results on 
whether the dying process is shortened if IV fluids and nutri-
tion are not given, the patient’s comorbidities, cultural view-
points, religion, level of consciousness, physical condition, level 
of thirst, and risk of pulmonary edema should be considered 
before making a decision. No medication has been proven to 
improve loss of appetite and cachexia in patients in the dying 
process.
Recommendation 1. Provision of IV Fluids and Nutrition
Evidence Recommendation
We recommend that before providing intravenous (IV) fluids and nutrition to patients in the dying process, 
benefits and risks should be evaluated in terms of the patient’s degree of thirst, whether the patient is 




Medical interventions to identify and assess correctable causes of dyspnea in patients in the dying process 
should be considered. When considering medication or invasive treatments, the benefits and harm should be 
evaluated against providers’ clinical opinions and patients’ care requirements.
D IIa
Recommendation 3. Non-Pharmacological Treatment of Dyspnea
Evidence Recommendation
In order to ameliorate dyspnea in patients in the dying process, position changes and other non-pharmacological 
treatments such as improvements in the environment and psychological relaxation should be considered.
D IIa
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It is important to ease the patient’s pain by identifying cor-
rectable causes of dyspnea and addressing them through 
pharmacological or non-pharmacological treatment, while 
simultaneously easing the concerns of the patient and fam-
ily members by explaining future treatment plans in order 
to prevent anxiety-induced exacerbation of dyspnea. Dur-
ing the dying process, a broad range of symptoms related to 
dyspnea occur, and some patients do not respond to non-
invasive treatments such as oxygen and diuretics. The benefits 
and harms associated with additional bloodwork or imaging-
based diagnoses should be considered, and if the treatment 
under discussion is invasive, careful consideration should be 
made before conducting a test.
In order to improve dyspnea in patients in the dying process, 
room air should be circulated by opening windows, and ad-
equate temperature and humidity should be maintained. It is 
helpful to raise the patient’s head and to place an electric fan 
to direct a weak flow of air towards the patient’s face. When 
the patient is conscious, he or she should be instructed to in-
hale deeply through the nose and exhale for as long as possible 
through the mouth with lips contracted.
In patients who have not previously received opioids, 5~10 
mg of morphine can be administered orally. If oral adminis-
tration is difficult, 2.5~5 mg can be given intravenously at 2- 
to 4-hour intervals depending on symptoms. If opioids are 
already being used for pain control, a 25% increase of the total 
daily dose can be considered. If dyspnea abruptly develops, an 
additional 10% of the total daily dose can be added. If the ef-
fect of opioids is insufficient or symptoms deteriorate due to 
anxiety, benzodiazepines can also be administered.
The effect of using oxygen for patients in the dying process 
with dyspnea has not been established. Since some patients 
experience dyspnea due to anxiety, administering oxygen to 
every patient with dyspnea should be avoided. However, if the 
cause of dyspnea is known to be hypoxia or if hypoxia is clin-
ically suspected, oxygen can be considered, and if the symp-
toms improve, oxygen should be maintained. However, there 
is no need to check oxygen saturation to assess the presence of 
hypoxia, and when oxygen saturation is low but no symptoms 
are present, oxygen is not required. 
Medical staff should first understand the cause of respiratory 
secretions and assess the impacts of respiratory secretions on 
Recommendation 4. Pharmacological Treatment of Dyspnea 
Evidence Recommendation
Opioids can be considered to improve dyspnea in patients in the dying process. If their effect is insufficient, and 
especially if symptoms deteriorate due to anxiety, benzodiazepines can be added.
B IIa
Recommendation 5. Oxygen Administration
Evidence Recommendation
Oxygen is not conventionally administered to patients in the dying process to improve dyspnea. If the cause of 
dyspnea is known to be hypoxia or if hypoxia is clinically suspected, oxygen can be considered.
C IIa
Recommendation 6. Management of Respiratory Secretions 
Evidence Recommendation
The use of suction to remove the respiratory secretions of patients in the dying process can be burdensome for patients 
due to irritation from catheters, so the choice of whether to use suction should be determined after evaluating the 
benefits and harms in terms of the amount of secretions, the patient’s status, and the caregiver’s needs.
D IIa
Recommendation 7. Pharmacological Treatment of Respiratory Secretion
Evidence Recommendation
Pharmacological treatments to suppress respiratory secretions can be considered for patients in the dying process. C IIb
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patients and family members. The catheter used in oropharyn-
geal suction does not reach all of the secretions, so oropha-
ryngeal suction is not very effective and can irritate the patient, 
making him or her suffer more. 
Medications to manage respiratory secretions are not com-
monly given to patients in the dying process, but if the se-
cretions are causing discomfort, medications (e.g., atropine, 
glycopyrronium bromide, hyoscine butylbromide/hyoscine 
hydrobromide, and scopolamine) can be started. Symptoms 
should be checked every 4~12 hours, and side effects such as 
delirium, anxiety, and excessive drowsiness should be moni-
tored (especially when atropine or hyoscine hydrobromide is 
used). If any discomfort due to respiratory secretions remains 
after 12 hours, the medication should be discontinued or 
switched to another drug. When urine retention, delirium or 
anxiety, excessive sedation, or discomfort due to dry mouth 
occurs, the medication should be discontinued or switched to 
another drug.
Clinicians should investigate whether nausea or vomiting is 
caused by medication (opioids, digoxin, steroids, antibiotics, 
anticonvulsants, and cytotoxic agents), radiation treatment, 
psychological causes, electrolyte imbalance, increased intra-
cranial pressure, severe constipation, ascites, gastric paraly-
sis, or bowel paralysis or obstruction and whether the cause 
is reversible. Moreover, the timing, duration and frequency, 
amount, triggering or ameliorating factors, and accompany-
ing symptoms should be evaluated. The degree of dehydration 
should be assessed based on vital signs and by examining the 
oral cavity and the abdomen. Possible associations with bowel 
obstruction or encephalopathy should be investigated through 
a digital rectal examination and an interview, respectively. The 
results of the above evaluations should be jointly considered to 
determine whether an intervention will be given for nausea or 
vomiting. 
It is difficult for patients with severe nausea or vomiting to 
take medicine orally, so an alternative method of administra-
tion should be identified. Glucocorticoids are considered when 
intracranial pressure increases, an acetylcholinergic antagonist 
(scopolamine) when the cause is vestibular organ dysfunc-
tion, and metoclopramide when gastric paralysis occurs. When 
nausea or vomiting is caused by bowel obstruction, hyoscine 
butylbromide is considered first, and if the symptoms do not 
Recommendation 8. Evaluation of Nausea or Vomiting
Evidence Recommendation
We recommend that nausea or vomiting in patients in the dying process should be evaluated comprehensively by assessing 
possible causes, related factors, and the degree of nausea or vomiting and by performing a physical examination.
D I
Recommendation 9. Pharmacological Treatment of Nausea or Vomiting
Evidence Recommendation
Validated pharmacological treatments should be considered based on the cause, related factors, and degree of 
nausea or vomiting in patients in the dying process.
C IIa
Recommendation 10. Evaluation of Pain
Evidence Recommendation
We recommend that the pain of patients in the dying process should be regularly evaluated throughout the 
dying process.
D I
Recommendation 11. Pharmacological Treatment of Pain
Evidence Recommendation
When patients in the dying process experience pain, immediate and proactive pain management by 
selecting an effective medication should be considered.
D IIa
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improve after 24 hours of administration, octreotide can be 
considered. When nausea or vomiting is caused by opioids, a 
different type of opioid should be tried.
Pain should be regularly evaluated in every patient, includ-
ing those who are unconscious. If the patient has difficulty 
describing his or her own level of pain (e.g., in patients with 
dementia or developmental problems), pain can be evaluated 
using specialized behavioral pain assessment tools. For dying 
patients in the critical care unit, the Critical Care Pain Obser-
vation Tool can be used to evaluate pain.
When patients in the dying process experience uncontrolled 
pain, opioids are given based on the level of pain, and the dose 
of the opioid should be controlled proactively. For patients 
dying due to deterioration of their diseases, an increased dos-
age of opioids may be required. This requirement should not 
be confused with tolerance, and the administration of pain 
medication should not be delayed. Oral administration should 
be considered first, and when necessary, the method of deliv-
ery (intraoral, intravenous, rectal, subcutaneous, sublingual, 
intramucosal, epidural, or intrathecal) may be adjusted after 
calculating the equivalent dose.
Clinicians should consider discontinuing medications that are 
not effective in symptom management or that can be harmful. 
Discussions with the patient and family members should pre-
cede any decision. When an adjustment of the administration 
method is necessary due to a change in the patient’s status, the 
most effective method should be chosen based on whether the 
patient can safely swallow the medication and the patient’s 
preferences.
The aim of administering sedative medication when death 
is near is to reduce consciousness or to induce unconscious-
ness in order to reduce severe pain. A systematic review of the 
literatures found that palliative sedation did not influence the 
length of survival among patients in the dying process [15]. 
Before palliative sedation is administered, it should be inves-
tigated whether all possible treatments have been conducted 
and whether decision-making or adjustment regarding the 
prognosis is necessary. When possible, patients themselves and 
their family members should be involved in the discussion of 
the reasons for and aims of palliative sedation. The patient’s 
Recommendation 12. Planning of Medication Use
Evidence Recommendation
Medical staff should review the current medications taken by patients in the dying process and consider 
discontinuing unnecessary medication. For medications taken for symptom management, changes in the 
dose and method of administration should be considered according to changes in the patient’s status.
D IIa
Recommendation 13. Palliative Sedation
Evidence Recommendation
For severe symptoms that do not improve with available treatments in patients in the dying process, 
palliative sedation may be considered.
D IIb
Recommendation 14. Evaluation of Delirium
Evidence Recommendation
When the psychological status or level of consciousness of patients in the dying process changes, 
evaluation of delirium should be considered.
D IIa
Recommendation 15. Non-Pharmacological Interventions for Delirium
Evidence Recommendation
The use of physical restraints, indwelling catheters, and intravenous injections should be minimized in patients 
in the process of dying who experience delirium, and non-pharmacological interventions, such as an adequate 
explanation of any treatments and self-care, are recommended.
B I
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religion, sociocultural preferences, current wishes, and goals of 
care should be considered.
Midazolam is most commonly used for sedation because its 
half-life and onset time are short, and sedation occurs pro-
portionally to dosage. Otherwise, lorazepam or diazepam, 
which have a longer half-life, can be chosen as well.
Delirium is evaluated using the criteria in the Diagnostic and 
Statistical Manual of Mental Disorders-5. However, validated 
diagnostic tools for delirium have limited applicability in pa-
tients during the dying process, especially for patients with hy-
poactive delirium, a low level of consciousness, and impaired 
communication. The medical staff should review possible 
reversible causes of delirium such as pain, bladder or rectal 
bloating, metabolic disorders such as hyponatremia, and drugs 
(steroids, anticholinergics, narcotic analgesics, psychotropic 
drugs) and intervene accordingly. 
Physical restraints should not be used in dying patients who 
experience delirium because they increase the risk of compli-
cations such as diminished function, cognitive decline, injury, 
suffocation, and death [11]. However, when patients pose 
a risk of physical injury for themselves and others or when 
pharmacological treatments have been tried without effect, 
physical restraints can be considered in exceptional cases when 
the potential benefit (safety) outweighs the potential risk (anx-
iety/increase in agitation). Even in such cases, the least limiting 
method should be used for the least amount of time.
Antipsychotics are first-line medications for the pharma-
cological management of delirium in patients in the dying 
process, except for delirium resulting from alcohol or benzo-
diazepine withdrawal. Generally, high-potency medications 
are preferred over low-potency medications. Haloperidol is 
recommended as a first-line medication. The starting dose of 
haloperidol is 0.5~2 mg (subcutaneous or intramuscular), and 
the dose should be increased every 1~2 hours until symptoms 
improve. However, the patient should be observed since there 
is a risk of QT prolongation. In order to reduce the extra-
pyramidal side effects of haloperidol, atypical antipsychotic 
medications (risperidone, olanzapine, quetiapine) can be con-
sidered.
Reversible causes of anxiety or agitation (pain, bladder or 
Recommendation 16. Pharmacological Treatment of Delirium
Evidence Recommendation
Antipsychotics may be considered as the first-line pharmacological treatment for delirium in patients in the 
dying process.
B IIb
Recommendation 17. Interventions for Anxiety or Agitation
Evidence Recommendation
Non-pharmacological or pharmacological interventions for anxiety or agitation are recommended in 
patients in the dying process based on an assessment of the causes and history of anxiety disorders.
D I
Recommendation 18. Psychological Support (Communication with the Patient)
Evidence Recommendation
In order to provide psychological and spiritual support for a sense of loss, lamentation, worry, and 
fear, the medical staff should consider a holistic assessment that encompasses patients’ physical, 
psychological, social, and spiritual condition.
D IIa
Recommendation 19. Effective Communication
Evidence Recommendation
Medical staff should consider providing psychological and spiritual support to patients in the dying 
process and their family members through appropriate and effective communication methods.
D IIa
Guideline in the Dying Process
109Vol. 23 • No. 3 • September 2020 www.kjhpc.org
rectal bloating, fever, electrolyte imbalance, drug use or with-
drawal symptoms, unnecessary monitoring equipment), history 
of anxiety disorders, and spiritual issues should be evaluated 
comprehensively. Factors that interfere with peaceful death 
should be addressed by steps such as discontinuing unneces-
sary monitoring, turning off the alarms of the equipment, and 
adjusting the brightness of monitor screens. The medications 
in use should be evaluated regularly, and unnecessary medica-
tions should be discontinued. Benzodiazepines can be con-
sidered to address anxiety or anxiousness, and pain should be 
managed proactively. Throughout the dying process, sufficient 
explanations about future steps and support should be given.
As explanations and information about the treatment process 
are provided, clinicians should evaluate patients’ and family 
members’ internal distress caused by a sense of loss, mourn-
ing, lamentation, worry, and fear. Simultaneously, their val-
ues, meaning of illness, and religiosity, hope or inner strength 
should be understood. The appropriate spiritual or religious 
ceremonies after death and wishes of family members should 
be acknowledged.
The process through which medical staff establish trust and 
maintain an appropriate relationship with the patient and 
family is of the utmost importance. It is recommended that 
medical staff provide specific comments on the patient’s emo-
tions (e.g., “You look a bit sad today,” “I know that the last 
few months must have been difficult for you”), use supportive 
phrasing (“My heart aches to hear that you had such a hard 
time; I hope we can try to improve your quality of life to-
gether”), and ask what patients are worried about most (“Can 
you tell me what worries you most at this moment?”, “Which 
aspect is most difficult for you?”, “In order for me to under-
stand your situation better, can you tell me how you feel?”) [4]. 
Medical staff should provide psychological and social support 
by having a compassionate attitude and trying to understand 
patients and their family members.
Shared decision-making is the process of establishing an 
individualized treatment plan by the patient, family, and the 
doctor considering what is most beneficial for the patient and 
which treatment best reflects the patient’s values and prefer-
ences. For shared decision-making, the medical team should 
build trust by suggesting that patients and their family mem-
bers should think about what the best option is together (team 
Recommendation 20. Decision-Making (Communication among Patients, Family Members, and Medical Staff)
Evidence Recommendation
To provide high-quality end-of-life care, shared decision-making with the patient, family members and 
medical staff is recommended.
C I
Recommendation 21. Advance Decision-Making
Evidence Recommendation
We recommend that medical staff make advance decisions with patients in the dying process and their 
family members as soon as possible.
D I
Recommendation 22. Sharing and Confirming Decisions
Evidence Recommendation
We recommend that medical staff regularly check whether patients and family members have requests and 
document them to share with the medical staff.
D I
Recommendation 23. Evaluation of Family Care
Evidence Recommendation
To provide care for family members of patients in the dying process, a comprehensive and holistic 
assessment should be conducted.
D IIa
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talk), explain the expected benefits and risks of treatment 
methods applicable to the patients (option talk), and help with 
making an appropriate decision (decision talk).
In order to provide high quality end-of-life care, the medi-
cal staff should first form a consensus about prognosis and 
treatment methods and explain the plan to patients and family 
members when everyone is present. The medical staff should 
seek appropriate timing for advance decisions so that discus-
sions can take place when the situation is not urgent.
The decision-making process is influenced by factors such as 
the communication skills of medical staff, clinical experience, 
relationships with patients, and disagreements among family 
members. When a care plan is established regarding the prog-
nosis of patients in the dying process, the medical staff should 
document the plan clearly. The documentation is not limited 
to advance directives. The patient’s wishes about end-of-life 
care (e.g., location of death) should be applicable regardless 
of the type of medical institution; therefore, the results of the 
decision-making process should be documented and shared 
with the medical staffs.
The medical staff should understand the strengths and limi-
tations of the family, such as resilience, sociocultural support 
system, the effects of diseases, prior experiences of disease 
and loss, drug abuse, neglect, and risk of abuse. The family’
s needs for care or support should be understood considering 
their education, occupation, hobbies, and economic activities, 
as well as changes of family members. The patient’s and fam-
ily’s capacity of care, such as as using appropriate equipment, 
changing the home structure, or transportation, should be 
evaluated. Resources in the community, financial support, and 
needs for rest should also be considered. Through a compre-
hensive and holistic evaluation, medical staff should strive to 
Recommendation 24. Provision of Individualized Family Care
Evidence Recommendation
Medical staff should evaluate the risk factors for complicated grief in family members and consider providing 
services for the family members (including caregivers).
D IIa
Recommendation 25. Education for Patients and their Family Members 
Evidence Recommendation
Medical staff should provide information about end-of-life care to patients in the dying process and their family 
members and should consider checking whether they understand that information.
D IIa
Recommendation 26. Roles of the Team Members (Communication among Members of the Medical Team)
Evidence Recommendation
In order to provide patient-centered end-of-life care, it is recommended to form a multidisciplinary team 
that consists of doctors, nurses, social workers, and others, and to communicate clearly and in a cooperative 
manner.
C I
Recommendation 27. Education of Medical Staff
Evidence Recommendation
Professional training for medical staff who care for patients in the dying process is recommended. D I
Recommendation 28. Medical Team Care
Evidence Recommendation
Medical institutions, in order to provide high quality end-of-life care, should proactively manage the health and 
work satisfaction of the medical staff.
C IIa
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understand the family structure and functions in order to plan 
for decision-making processes.
It is suggested to send condolence letters that contain infor-
mation about grief support on a regular basis, but it may also 
be appropriate to consider connecting the family to organiza-
tions that specialize in grief and bereavement support.
Medical staff should provide information about possible 
changes in the dying process, including physical symptoms, to 
improve the coping ability of family members. It is especially 
important to inform patients and their family members about 
delirium, changes in consciousness, and changes in breathing.
When a multidisciplinary team is involved, the level of sat-
isfaction of patients and family members increase, and it is 
beneficial for addressing grief. Communication among the 
team members should be cooperative and accurate. The role 
and responsibilities of each member should be clear. The team 
leader should emphasize horizontal communication within the 
team, and the team should debrief to identify problems and 
improve upon them.
Medical institutions should develop a training program that 
specifies the role of each member of the medical staff. In the 
dying process, decision-making involves the patient, family, 
and a multidisciplinary team, so the medical staff must be able 
to establish a preliminary assessment plan and have enough 
clinical knowledge to respond to unexpected situations effec-
tively. Medical institutions should provide sufficient education 
for the staff to confirm deaths and provide a death declaration 
in an appropriate manner.
The distress of medical staff who experience loss of patients 
and mourning causes burnout, compassion fatigue, and moral 
pressure, which both affect the health of medical staff and can 
influence the care environment for patients. Leaders of the 
medical staff should confirm whether any team members can-
not participate in carrying out advance directives due to per-
sonal beliefs or values, express respect for their opinions, and 
not burden them with participating in the implementation of 
advance directives. Medical institutions should manage team 
members at a high risk of burnout and create a work environ-
ment and culture where related issues can be improved.
CONCLUSION
Limited evidence reflects the differences in personnel and 
resources across medical institutions, but this guideline is 
meaningful in that it provides recommendations that reflect 
the realities of clinical practice in South Korea. This guidance 
was developed with doctors and nurses in general wards in 
mind, but it can be utilized in primary care settings, rehabilita-
tion institutions (physical therapists) or institutions providing 
mental health care (counselors), and care hospitals or home 
care teams, as well as by medical staff who are caring for end-
of-life patients for the first time. It is also expected to be use-
ful when there are conflicts in the decision-making process 
among patients, family, and medical staff. Shared decision-
making (communication among patients, family members, and 
the medical staff) and team roles (in particular, education of 
medical staff) are important factors for providing end-of-life 
care to patients, and are also areas that require improvement. 
We hope that this guideline will be a step towards the ultimate 
aim of ameliorating pain in patients in the dying process, pro-
viding them with a holistic sense of peace, and allowing the 
dying process to be the completion of the patient’s life.
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Supplementary Table 1. Levels of Evidence and Recommendations
Evidence level Definition
A Evidence for the recommendation is clear (one or more randomized controlled trial, meta-analysis, or systematic literature 
review) 
B Evidence for the recommendation is trustworthy (one or more well-designed non-randomized clinical study, such as a case-
control or cohort study)
C Evidence for the recommendation exists, but is not trustworthy (low level of related evidence from observational studies or 
case reports) 
D Evidence for recommendation is based on expert opinions drawing upon clinical experience and expertise 
Recommendation level Definition Phrasing of recommendation
Class I The evidence level and benefits are clear, and the recommendation has 
high utility in clinical practice.
Is recommended
Class IIa The evidence level and benefits are credible, and the recommendation 
has high or medium utility in clinical practice.
Should be considered
Class IIb The evidence level and benefits are not credible, but the utility in clinical 
practice is high or medium.
May be considered
Class III The evidence level is not credible, the recommendation may cause 
harm, and its utility in clinical practice is low. 
Is not recommended
